Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q


Published in:
American Journal of Human Genetics

Citation for published version (APA):

Report

Two Families with Familial Amyotrophic Lateral Sclerosis Are Linked to a Novel Locus on Chromosome 16q

Deborah M. Ruddy,1 Matthew J. Parton,2 Ammar Al-Chalabi,3 Cathryn M. Lewis,1 Caroline Vance,2 Bradley N. Smith,2 P. Nigel Leigh,2,3 John F. Powell,4 Teepu Siddique,5 Eelco Postumus Meyjes,6 Frank Baas,6,7 Vianney De Jong,6 and Christopher E. Shaw1,2,3

Departments of 1Medical and Molecular Genetics and 2Neurology, Guy’s, King’s, and St. Thomas’ School of Medicine, and Departments of 3Neurology and 4Neuroscience, Institute of Psychiatry, London; 5Department of Neurology, Northwestern University, Chicago, IL; and Departments of 6Neurology and 7Molecular Biology, Academic Medical Centre, Amsterdam

Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset disease in which motor neurons in the brain and spinal cord degenerate by largely unknown mechanisms. ALS is familial (FALS) in 10% of cases, and the inheritance is usually dominant, with variable penetrance. Mutations in copper/zinc super oxide dismutase (SOD1) are found in 20% of familial and 3% of sporadic ALS cases. Five families with ALS and frontotemporal dementia (ALS-FTD) are linked to 9q21, whereas one family with pure ALS is linked to 18q21. We identified two large European families with ALS without SOD1 mutations or linkage to known FALS loci and conducted a genomewide linkage screen using 400 microsatellite markers. In both families, two-point LOD scores >1 and a haplotype segregating with disease were demonstrated only across regions of chromosome 16. Subsequent fine mapping in family 1 gave a maximum two-point LOD score of 3.62 at D16S3137 and a three-point LOD score of 3.85 for markers D16S415 and D16S3137. Haplotype analysis revealed no recombination between markers at D16S3075 and D16S3112. The maximum two-point LOD score for family 2 was 1.84 at D16S415, and the three-point LOD score was 2.10 for markers D16S419 and D16S415. Definite recombination occurred in several individuals, which narrowed the shared haplotype in affected individuals to a 10.1-cM region (flanking markers: D16S3396 and D16S3112). The region shared by both families on chromosome 16q12 corresponds to ∼4.5 Mb on the Marshfield map. Bioinformatic analysis of the region has identified 18 known genes and 70 predicted genes in this region, and sequencing of candidate genes has now begun.

Amyotrophic lateral sclerosis (ALS) is a greatly disabling and ultimately fatal neurodegenerative disease. Muscles become progressively atrophic and weak because of degeneration of motor neurons in the brain and spinal cord. Death due to respiratory failure occurs, on average, 3.5 years after symptom onset (Haverkamp et al. 1995; Shaw et al. 2001). The incidence of ALS is 1–2 per 100,000, but, because survival is relatively short, the prevalence is only ∼4–7 per 100,000 (Kondo 1995). In familial ALS (FALS), the vast majority of affected individuals have an autosomal dominant pattern of inheritance. FALS accounts for 5%–10% of cases, and they are clinically and pathologically indistinguishable from sporadic disease (Rouleau et al. 1996; Shaw et al. 1997). Linkage to chromosome 21q22.11 was demonstrated in a subset of kindreds with FALS (Siddique et al. 1991), and mutations in SOD1 (ALS1 [MIM 105400]) were subsequently found in 20% of FALS and 3% of sporadic ALS cases (Rosen et al. 1993; Shaw et al. 1998). Over 100 SOD1 mutations have now been reported, and the vast majority are missense, which result in the substitution of a single amino acid (Shaw et al. 2001). Mice transgenic for mutant SOD1 develop motor neuron degeneration by a toxic gain of function, but whether this is due to altered metal ion handling, catalytic function, or protein misfolding and aggregation is still debated (Cleveland et al. 2001).
A recessive form of juvenile-onset primary lateral sclerosis (ALS2 [MIM 205100]) was linked to chromosome 2q33 (Hentati et al. 1994), and truncating mutations have been detected in ALS2/alsin (Hadano et al. 2001; ALS2/alsin [MIM 602433]) (Chance et al. 1998), 15q15-21 in kindreds with recessive juvenile onset (Hentati et al. 1998), and 9q21 in five families with ALS with frontotemporal dementia (ALS-FTD [MIM 105550]) (Hosler et al. 2000). Mutations in tau have been detected in families with frontotemporal de-mentia (FTD) and Parkinsonism (FTDP) linked to 17q21 (MIM 157140) (Hutton et al. 1998), but only rarely are family members affected by an ALS-like syndrome. The vast majority (80%) of kindreds with dominant FALS are unlinked.

We identified two large unrelated European kindreds with ALS that were suitable for linkage. A consultant neurologist examined all individuals (F1: C.E.S. and P.N.L.; F2: V.D.J. and E.P.M.). ALS was confirmed by use of PEDCHECK software (ABI Biosystems). A consultant neurologist examined all individuals (F1: C.E.S. and P.N.L.; F2: V.D.J. and E.P.M.).

### Table 1

<table>
<thead>
<tr>
<th>FAMILY AND MARKER</th>
<th>MARKER POSITION</th>
<th>LOD SCORE AT θ =</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D16S423</td>
<td>10.36</td>
<td>−∞</td>
<td>−1.31</td>
<td>−5.5</td>
<td>−2</td>
<td>−0.5</td>
<td></td>
</tr>
<tr>
<td>D16S404</td>
<td>18.07</td>
<td>1.06</td>
<td>−0.75</td>
<td>−0.49</td>
<td>−2.4</td>
<td>−0.06</td>
<td></td>
</tr>
<tr>
<td>D16S3075</td>
<td>23.28</td>
<td>−∞</td>
<td>−0.87</td>
<td>−0.71</td>
<td>−0.39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D16S3103</td>
<td>32.07</td>
<td>1.75</td>
<td>1.44</td>
<td>1.10</td>
<td>−0.73</td>
<td>−0.36</td>
<td></td>
</tr>
<tr>
<td>D16S3046</td>
<td>40.65</td>
<td>2.48</td>
<td>2.15</td>
<td>1.73</td>
<td>1.12</td>
<td>−0.65</td>
<td></td>
</tr>
<tr>
<td>D16S403</td>
<td>43.89</td>
<td>1.12</td>
<td>0.98</td>
<td>0.76</td>
<td>−0.50</td>
<td>−0.23</td>
<td></td>
</tr>
<tr>
<td>D16S3068</td>
<td>48.53</td>
<td>1.49</td>
<td>1.19</td>
<td>0.89</td>
<td>−0.58</td>
<td>−0.28</td>
<td></td>
</tr>
<tr>
<td>D16S769</td>
<td>50.6</td>
<td>1.21</td>
<td>1.06</td>
<td>0.83</td>
<td>−0.55</td>
<td>−0.26</td>
<td></td>
</tr>
<tr>
<td>D16S753</td>
<td>57.79</td>
<td>2.08</td>
<td>1.81</td>
<td>1.43</td>
<td>−0.98</td>
<td>−0.49</td>
<td></td>
</tr>
<tr>
<td>D16S409</td>
<td>58.46</td>
<td>0.18</td>
<td>0.04</td>
<td>−0.01</td>
<td>0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D16S517</td>
<td>58.46</td>
<td>0.41</td>
<td>0.19</td>
<td>−0.10</td>
<td>0.03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D16S3044</td>
<td>58.46</td>
<td>3.34</td>
<td>2.77</td>
<td>2.15</td>
<td>1.48</td>
<td>0.76</td>
<td></td>
</tr>
<tr>
<td>D16S3136</td>
<td>62.11</td>
<td>2.27</td>
<td>1.95</td>
<td>1.55</td>
<td>1.09</td>
<td>0.57</td>
<td></td>
</tr>
<tr>
<td>D16S3396</td>
<td>63.78</td>
<td>1.15</td>
<td>−0.89</td>
<td>−0.63</td>
<td>−0.38</td>
<td>−0.17</td>
<td></td>
</tr>
<tr>
<td>D16S419</td>
<td>67.4</td>
<td>1.42</td>
<td>1.14</td>
<td>0.85</td>
<td>−0.55</td>
<td>−0.26</td>
<td></td>
</tr>
<tr>
<td>D16S415</td>
<td>67.62</td>
<td>3.50</td>
<td>2.93</td>
<td>2.25</td>
<td>1.54</td>
<td>−0.79</td>
<td></td>
</tr>
<tr>
<td>D16S3207</td>
<td>69.65</td>
<td>3.62</td>
<td>3.01</td>
<td>2.34</td>
<td>1.61</td>
<td>−0.83</td>
<td></td>
</tr>
<tr>
<td>D16S3163</td>
<td>72.3</td>
<td>0.26</td>
<td>0.22</td>
<td>0.17</td>
<td>0.10</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>D16S3053</td>
<td>73.91</td>
<td>1.01</td>
<td>0.88</td>
<td>0.61</td>
<td>0.29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D16S403</td>
<td>73.2</td>
<td>0.26</td>
<td>0.22</td>
<td>0.17</td>
<td>0.10</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>D16S3054</td>
<td>73.91</td>
<td>1.01</td>
<td>0.88</td>
<td>0.61</td>
<td>0.29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D16S3053</td>
<td>73.91</td>
<td>1.01</td>
<td>0.88</td>
<td>0.61</td>
<td>0.29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D16S403</td>
<td>73.91</td>
<td>1.01</td>
<td>0.88</td>
<td>0.61</td>
<td>0.29</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE.**—Markers within the disease haplotype are in italics.

### Ethics

Ethical committees in both clinical centers approved genetic research on ALS. Following receipt of informed consent, blood was drawn and DNA extracted from 48 members of F1 (5 affected) and 146 members of F2 (5 affected). By genotyping the spouses and offspring, we were able to recreate the genotypes and haplotypes of deceased affected individuals (5 in F1 and 1 in F2) (see fig. 1). No mutations in SOD1 were detected by sequencing two affected members from each family (as described in Shaw et al. [1998]). Tau mutations were excluded by direct sequencing in two members of F2 (as described in Rizzu et al. [1999]). In both families, linkage to reported ALS loci was confidently excluded for 1q21 (maximal two-point LOD scores of 0.33 for D18S846 [F1] and of 0.31 at D18S35 [F2] and 9q21 (LOD scores of 0.32 at D9S1122 [F1] and of −0.8 at D9S922 [F2]).

Power calculations were made, by use of SLINK, for a single marker with six alleles (Ott 1989; UK Human Genome Mapping Project Resource Centre). The maximum achievable LOD score, for 19 members of F1, was 3.06 and, for 35 members of F2, was 2.04 (by use of 100 replications and identical assumptions as for FASTLINK; see below). A fluorescent dye-labeled medium-density microsatellite marker set (~10-CM map, PRISM) was used for genotyping, and the PCR products were run out on ABI 377 and 3100 sequencers and analyzed by use of GENOTYPER software (ABI Biosystems). A consistent genotype was obtained in 95% of alleles, and inheritance was checked, by use of PEDCHECK.
Figure 1  Pedigree drawing of families 1 and 2. Affected individuals are indicated by blackened diamonds. The informative marker alleles are shown. All inferred haplotypes reconstructed (in brackets) were done on the basis of minimal recombination. A hatched bar indicates the disease haplotype. Information is shown only for relevant individuals. The sex of all individuals has been disguised, and unaffected at-risk individuals have been omitted to preserve confidentiality.
Figure 2  Graphical representation of the three-point LOD scores for F1 and F2

A   3-point LOD scores, Family 2, Chromosome 16 locus

B   3-point LOD scores, Family 1, Chromosome 16 locus
and 1.80 at D16S3137 ( ) (table 1). The maximum LOD scores LINK (data submitted for review but not shown). In SLINK; see above) and tested for linkage by use of FASTLINK (O'Connell and Weeks 1998; UK Human Genome Mapping Project Resource Centre) was used with the following assumptions: autosomal dominant inheritance with age-dependent penetrance, no phenocopies, a disease gene frequency of 0.00001, and equal marker allele frequencies. The age cutoff for liability classes was based on reports published elsewhere (Hand et al. 2002) and modified with penetrance calculated in each family: (1) age <46 years, F1 = 50%, F2 = 20%; (2) age >46 years, F1 = 85%, F2 = 40%; and (3) spousal was given the background population risk.

Given the very large number of individuals in both pedigrees, we chose an “affecteds-only” analysis. Genotyping of 385 markers was initially performed on 5 affected individuals from F1 (with an additional 12 unaffected spouses and offspring) and tested for linkage by use of FASTLINK (data submitted for review but not shown). In F1, only two regions generated LOD scores >1.0: chromosome 16 (D16S415, LOD = 3.5, and D16S3136, LOD = 2.27) and chromosome 9 (D9S1677 LOD = 1.68). The maximum three-point LOD score across chromosome 9 was only 0.251, and SIMWALK 2.82 (Weeks et al. 1995) produced no shared haplotype in the affected individuals. In F2, there were three regions with LOD scores ~1.0: chromosome 16 (D16S415, LOD = 1.84), chromosome 6 (D6S460, LOD = 1.01), and chromosome 11 (D11S904, LOD = 0.97), but the maximum three-point LOD scores were 0.18 and 0.23 for chromosomes 6 and 11, respectively; again, haplotype analysis excluded these regions.

The region on chromosome 16 was fine mapped with the scores were more modest, but seven markers had LOD scores >2 in F1, with a maximal two-point LOD score of 2.46 for markers D16S419 and D16S415 (fig. 2). Empirical P values for the maximum two-point LOD scores at chromosome 16, for F1, are P < .0001 and, for F2, are P < .01, by use of SLINK (Ott 1989). Although positive LOD scores were recorded between D16S403 and D16S517 in F2, a consistent haplotype could not be created from these genotypes, thus excluding linkage to this region. A shared haplotype was observed in the affected individuals of F2, and recombinant events in the affected individual III:7 narrowed the conserved haplotype to a 10.1-cM region (flanking markers: D16S3396 and D16S3112) (fig. 1). This haplotype was also seen in one unaffected sibling and one offspring of III:7 (reviewed but not depicted, to maintain confidentiality).

The overlapping region shared between the two families corresponds to 10.14 cM on the Marshfield map and ~4.5 Mb of sequenced genome. A systematic search of publicly available databases (Ensembl, NCBI, and UCSC) has identified 18 known and 70 putative genes in this region. Candidate genes, screened but, to date, without a mutation identified that segregates with disease, include: CAGF9, containing a polyglutamine tract of nine repeats; FTS, an ubiquitin-conjugating enzyme; CAPNS2, a cysteine protease subunit; and SALL1, a transcriptional regulator of higher chromatin order. We have begun screening the remaining genes for mutations, prioritized on the basis of their expression in the nervous system and potential role in the pathogenesis of ALS.

ALS is a rapidly fatal late-onset neurodegenerative disorder for which families suitable for linkage are very rare. Here, we report two unrelated kindreds that are linked to an overlapping region on chromosome 16q12-13. We are aware of two other unrelated families with ALS linked to regions of chromosome 16 that overlap this locus (R. H. Brown and J. de Belleroche, personal communication). This suggests that mutation of a gene in this region is a significant cause of FALS. The identification of another FALS gene will enable more families to undergo predictive and prenatal testing. It will also allow the development of transgenic and cellular models of ALS that will advance our understanding of disease mechanisms and help develop more effective therapies.

Acknowledgments

First and foremost, the authors thank the families who contributed to this project. This work was supported by clinical training fellowships from the Medical Research Council U.K. (to D.R.) and Wellcome Trust (to M.J.P.), Joint Research Committee of King’s College Hospital London (to B.N.S), Psychiatry Research Trust of the Institute of Psychiatry (to B.N.S. and C.V.), and the Motor Neurone Disease Association U.K.
Electronic-Database Information

Accession numbers and URLs for data presented herein are as follows:

Center for Medical Genetics, Marshfield Medical Research Foundation, http://research.marshfieldclinic.org/genetics/ (for marker position)
Ensembl, http://www.ensembl.org/ (for sequence and protein function information)
Genome Database, http://www.gdb.org/ (for marker and gene position)
National Center for Biotechnology Information (NCBI), http://www.ncbi.nlm.nih.gov/mapview/ (for marker and gene position, as well as sequence and protein function information)

Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim/ (for ALS1, ALS2, ALS3, ALS4, ALS-FTD, FTDP, and background information on loci)
UCSC Genome Bioinformatics, http://genome.ucsc.edu/ (for marker and gene position and sequence information)


References